Efficacy and Safety of Tofacitinib for Treatment of Moderate to Severe Active Ulcerative Colitis: First Report from Iran

Maryam Jameshorani ¹, Homayoon Vahedi ², Anahita Sadeghi ², Ali Reza Sima ², Amir Anushiravani ², Helia Nateghi beige ², Masoud M. Malekzadeh ², Shokoofeh Naserinejad ², Sudabeh Alatab ² *

Cited by CrossRef: 2

1- Dalal R, Sharma P, Bains K, Pruce J, Allegretti J. 1-Year Comparative Effectiveness of Tofacitinib vs Ustekinumab for Patients With Ulcerative Colitis and Prior Antitumor Necrosis Factor Failure. 2024;30(3):395 [Crossref]

2- Gialouri C, Moustafa S, Thomas K, Hadziyannis E, Vassilopoulos D. Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and real-world studies. Rheumatol Int. 2023;43(3):421 [Crossref]

3- Lin C, Liu W, Wan C, Wang H. Effectiveness of tofacitinib in patients with ulcerative colitis: an updated systematic review and meta-analysis of real-world studies. BMJ Open Gastroenterol. 2024;11(1):e001347 [Crossref]

Submit Your Paper Notification Instructions for Authors Aims and Scope Editorial policies Editorial Board AIM old site Archive

About Us

A Monthly Peer-Reviewed Medical Journal Published by the Academy of Medical Sciences of the I.R. Iran; Indexed in PubMed/MEDLINE, ISI Web of Science, EMBASE, SCOPUS, CINHAL, PASCAL, CSA, SID, ISSN: Print 1029-2977, Online 1735-3947.The impact factor of Archives of Iranian Medicine according to Journal Citation Reports® (JCR®) 2016 is 1.20.